CCG
REGN icon

Catalina Capital Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Catalina Capital Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-307
Closed -$219K – 324
2024
Q4 		$219K Sell
307
-36
-10% -$30.2K 0.07% 284
2024
Q3 		$361K Buy
343
+41
+14% +$45.6K 0.12% 177
2024
Q2 		$317K Buy
302
+52
+21% +$50.4K 0.12% 174
2024
Q1 		$241K Buy
+250
New +$238K 0.1% 218

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Catalina Capital Group's REGN Position: Q1 2025 in Review

Catalina Capital Group sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 307 shares — an estimated $219K sold.

Catalina Capital Group first reported a position in REGN in Q1 2024 and held it in 4 quarters. The position peaked at $361K in Q3 2024. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Catalina Capital Group reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Catalina Capital Group sold 307 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $219K.
  • Catalina Capital Group first reported a position in Regeneron Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Catalina Capital Group's Regeneron Pharmaceuticals position peaked at $361K in Q3 2024.
  • 1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Catalina Capital Group's 13F filing for Q1 2025, filed 21 Apr 2025.